by
Pfizer
on Tuesday laid out steering for the 2023 fiscal yr effectively under Wall Street consensus figures, tempering investor expectations forward of what it expects to be a steep drop in Covid-19 product gross sales.
Shares fell 3% in premarket buying and selling on the downbeat steering.
